The role and therapeutic potential of prohibitin in disease

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 6, 2011, Pages 1137-1143

  Theiss, Arianne L ^a   Sitaraman, Shanthi V ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Diabetes; Inflammation; Obesity; Prohibitin; Therapeutic

Indexed keywords

PROHIBITIN; PROHIBITIN 1; UNCLASSIFIED DRUG;

DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENTERITIS; HUMAN; INSULIN RESISTANCE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW;

DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATORY BOWEL DISEASES; MITOCHONDRIA; MODELS, BIOLOGICAL; NEOPLASMS; OBESITY; OXIDATIVE STRESS; REPRESSOR PROTEINS;

EID: 79955659650     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.01.033     Document Type: Review

References (93)

1. Altus M.S., Wood C.M., Stewart D.A., Roskams A.J., Friedman V., Henderson T., Owens G.A., Danner D.B., Jupe E.R., Dell'Orco R.T., et al. Regions of evolutionary conservation between the rat and human prohibitin-encoding genes. Gene 1995, 158:291-294.
2. Winter A., Kamarainen O., Hofmann A. Molecular modeling of prohibitin domains. Proteins 2007, 68:353-362.
3. Rastogi S., Joshi B., Fusaro G., Chellappan S. Camptothecin induces nuclear export of prohibitin preferentially in transformed cells through a CRM-1-dependent mechanism. J. Biol. Chem. 2006, 281:2951-2959.
4. Sharma A., Qadri A. Vi polysaccharide of Salmonella typhi targets the prohibitin family of molecules in intestinal epithelial cells and suppresses early inflammatory responses. Proc. Natl Acad. Sci. USA 2004, 101:17492-17497.
5. Nijtmans L.G., de Jong L., Artal Sanz M., Coates P.J., Berden J.A., Back J.W., Muijsers A.O., van der Spek H., Grivell L.A. Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins. EMBO J. 2000, 19:2444-2451.
6. Wang S., Fusaro G., Padmanabhan J., Chellappan S.P. Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene 2002, 21:8388-8396.
7. McClung J.K., Jupe E.R., Liu X.T., Dell'Orco R.T. Prohibitin: potential role in senescence, development, and tumor suppression. Exp. Gerontol. 1995, 30:99-124.
8. Eveleth D.D., Marsh J.L. Sequence and expression of the Cc gene, a member of the dopa decarboxylase gene cluster of Drosophila: possible translational regulation. Nucleic Acids Res. 1986, 14:6169-6183.
9. Sanchez-Quiles V., Santamaria E., Segura V., Sesma L., Prieto J., Corrales F.J. Prohibitin deficiency blocks proliferation and induces apoptosis in human hepatoma cells: molecular mechanisms and functional implications. Proteomics 2010, 10:1609-1620.
10. Du G., Mouithys-Mickalad A., Sluse F.E. Generation of superoxide anion by mitochondria and impairment of their functions during anoxia and reoxygenation in vitro. Free Radic. Biol. Med. 1998, 25:1066-1074.
11. Jones D.P. Redefining oxidative stress. Antioxid. Redox Signal. 2006, 8:1865-1879.
12. Durackova Z. Some current insights into oxidative stress. Physiol. Res. 2010, 59:459-469.
13. Theiss A.L., Idell R.D., Srinivasan S., Klapproth J.M., Jones D.P., Merlin D., Sitaraman S.V. Prohibitin protects against oxidative stress in intestinal epithelial cells. FASEB J. 2007, 21:197-206.
14. Henschke P., Vorum H., Honore B., Rice G.E. Protein profiling the effects of in vitro hyperoxic exposure on fetal rabbit lung. Proteomics 2006, 6:1957-1962.
15. Schleicher M., Shepherd B.R., Suarez Y., Fernandez-Hernando C., Yu J., Pan Y., Acevedo L.M., Shadel G.S., Sessa W.C. Prohibitin-1 maintains the angiogenic capacity of endothelial cells by regulating mitochondrial function and senescence. J. Cell Biol. 2008, 180:101-112.
16. Liu X., Ren Z., Zhan R., Wang X., Wang X., Zhang Z., Leng X., Yang Z., Qian L. Prohibitin protects against oxidative stress-induced cell injury in cultured neonatal cardiomyocyte. Cell Stress Chaperones 2009, 14:311-319.
17. Tsutsumi T., Matsuda M., Aizaki H., Moriya K., Miyoshi H., Fujie H., Shintani Y., Yotsuyanagi H., Miyamura T., Suzuki T., Koike K. Proteomics analysis of mitochondrial proteins reveals overexpression of a mitochondrial protein chaperon, prohibitin, in cells expressing hepatitis C virus core protein. Hepatology 2009, 50:378-386.
18. Theiss A.L., Laroui H., Obertone T.S., Chowdhury I., Thompson W.E., Merlin D., Sitaraman S.V. Nanoparticle-based therapeutic delivery of prohibitin to the colonic epithelial cells ameliorates acute murine colitis. Inflamm. Bowel. Dis. 2010.
19. Theiss A.L., Vijay-Kumar M., Obertone T.S., Jones D.P., Hansen J.M., Gewirtz A.T., Merlin D., Sitaraman S.V. Prohibitin is a novel regulator of antioxidant response that attenuates colonic inflammation in mice. Gastroenterology 2009, 137:199-208.
20. Liu C.Y., Lee C.F., Wei Y.H. Role of reactive oxygen species-elicited apoptosis in the pathophysiology of mitochondrial and neurodegenerative diseases associated with mitochondrial DNA mutations. J. Formos. Med. Assoc. 2009, 108:599-611.
21. Corral-Debrinski M., Horton T., Lott M.T., Shoffner J.M., Beal M.F., Wallace D.C. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat. Genet. 1992, 2:324-329.
22. Mawrin C., Kirches E., Krause G., Schneider-Stock R., Bogerts B., Vorwerk C.K., Dietzmann K. Region-specific analysis of mitochondrial DNA deletions in neurodegenerative disorders in humans. Neurosci. Lett. 2004, 357:111-114.
23. Navarro A., Boveris A. The mitochondrial energy transduction system and the aging process. Am. J. Physiol. Cell Physiol. 2007, 292:C670-C686.
24. Artal-Sanz M., Tavernarakis N. Prohibitin and mitochondrial biology. Trends Endocrinol. Metab. 2009, 20:394-401.
25. Berger K.H., Yaffe M.P. Prohibitin family members interact genetically with mitochondrial inheritance components in Saccharomyces cerevisiae. Mol. Cell. Biol. 1998, 18:4043-4052.
26. Merkwirth C., Langer T. Prohibitin function within mitochondria: essential roles for cell proliferation and cristae morphogenesis. Biochim. Biophys. Acta 2009, 1793:27-32.
27. Merkwirth C., Dargazanli S., Tatsuta T., Geimer S., Lower B., Wunderlich F.T., von Kleist-Retzow J.C., Waisman A., Westermann B., Langer T. Prohibitins control cell proliferation and apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria. Genes Dev. 2008, 22:476-488.
28. Sievers C., Billig G., Gottschalk K., Rudel T. Prohibitins are required for cancer cell proliferation and adhesion. PLoS ONE 2010, 5:e12735.
29. Kasashima K., Sumitani M., Satoh M., Endo H. Human prohibitin 1 maintains the organization and stability of the mitochondrial nucleoids. Exp. Cell Res. 2008, 314:988-996.
30. Muraguchi T., Kawawa A., Kubota S. Prohibitin protects against hypoxia-induced H9c2 cardiomyocyte cell death. Biomed. Res. 2010, 31:113-122.
31. Coates P.J., Jamieson D.J., Smart K., Prescott A.R., Hall P.A. The prohibitin family of mitochondrial proteins regulate replicative lifespan. Curr. Biol. 1997, 7:607-610.
32. Coates P.J., Nenutil R., McGregor A., Picksley S.M., Crouch D.H., Hall P.A., Wright E.G. Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence. Exp. Cell Res. 2001, 265:262-273.
33. Dell'Orco R.T., McClung J.K., Jupe E.R., Liu X.T. Prohibitin and the senescent phenotype. Exp. Gerontol. 1996, 31:245-252.
34. Nuell M.J., Stewart D.A., Walker L., Friedman V., Wood C.M., Owens G.A., Smith J.R., Schneider E.L., Dell' Orco R., Lumpkin C.K., et al. Prohibitin, an evolutionarily conserved intracellular protein that blocks DNA synthesis in normal fibroblasts and HeLa cells. Mol. Cell. Biol. 1991, 11:1372-1381.
35. Rizwani W., Alexandrow M., Chellappan S. Prohibitin physically interacts with MCM proteins and inhibits mammalian DNA replication. Cell Cycle 2009, 8:1621-1629.
36. Tsai H.W., Chow N.H., Lin C.P., Chan S.H., Chou C.Y., Ho C.L. The significance of prohibitin and c-Met/hepatocyte growth factor receptor in the progression of cervical adenocarcinoma. Hum. Pathol. 2006, 37:198-204.
37. Ren H.Z., Wang J.S., Wang P., Pan G.Q., Wen J.F., Fu H., Shan X.Z. Increased expression of prohibitin and its relationship with poor prognosis in esophageal squamous cell carcinoma. Pathol. Oncol. Res. 2010, 16:515-522.
38. Ryu J.W., Kim H.J., Lee Y.S., Myong N.H., Hwang C.H., Lee G.S., Yom H.C. The proteomics approach to find biomarkers in gastric cancer. J. Korean Med. Sci. 2003, 18:505-509.
39. He Q.Y., Cheung Y.H., Leung S.Y., Yuen S.T., Chu K.M., Chiu J.F. Diverse proteomic alterations in gastric adenocarcinoma. Proteomics 2004, 4:3276-3287.
40. Kang X., Zhang L., Sun J., Ni Z., Ma Y., Chen X., Sheng X., Chen T. Prohibitin: a potential biomarker for tissue-based detection of gastric cancer. J. Gastroenterol. 2008, 43:618-625.
41. Sato T., Sakamoto T., Takita K., Saito H., Okui K., Nakamura Y. The human prohibitin (PHB) gene family and its somatic mutations in human tumors. Genomics 1993, 17:762-764.
42. Nan Y., Yang S., Tian Y., Zhang W., Zhou B., Bu L., Huo S. Analysis of the expression protein profiles of lung squamous carcinoma cell using shot-gun proteomics strategy. Med. Oncol. 2009, 26:215-221.
43. Wu T.F., Wu H., Wang Y.W., Chang T.Y., Chan S.H., Lin Y.P., Liu H.S., Chow N.H. Prohibitin in the pathogenesis of transitional cell bladder cancer. Anticancer Res. 2007, 27:895-900.
44. Gu Y., Ande S.R., Mishra S. Altered O-GlcNAc modification and phosphorylation of mitochondrial proteins in myoblast cells exposed to high glucose. Arch. Biochem. Biophys. 2010.
45. Gregory-Bass R.C., Olatinwo M., Xu W., Matthews R., Stiles J.K., Thomas K., Liu D., Tsang B., Thompson W.E. Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis. Int. J. Cancer 2008, 122:1923-1930.
46. Ummanni R., Junker H., Zimmermann U., Venz S., Teller S., Giebel J., Scharf C., Woenckhaus C., Dombrowski F., Walther R. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer. Cancer Lett. 2008, 266:171-185.
47. Chumbalkar V.C., Subhashini C., Dhople V.M., Sundaram C.S., Jagannadham M.V., Kumar K.N., Srinivas P.N., Mythili R., Rao M.K., Kulkarni M.J., Hegde S., Hegde A.S., Samual C., Santosh V., Singh L., Sirdeshmukh R. Differential protein expression in human gliomas and molecular insights. Proteomics 2005, 5:1167-1177.
48. Mengwasser J., Piau A., Schlag P., Sleeman J.P. Differential immunization identifies PHB1/PHB2 as blood-borne tumor antigens. Oncogene 2004, 23:7430-7435.
49. Mishra S., Moulik S., Murphy L.J. Prohibitin binds to C3 and enhances complement activation. Mol. Immunol. 2007, 44:1897-1902.
50. Sato T., Saito H., Swensen J., Olifant A., Wood C., Danner D., Sakamoto T., Takita K., Kasumi F., Miki Y., et al. The human prohibitin gene located on chromosome 17q21 is mutated in sporadic breast cancer. Cancer Res. 1992, 52:1643-1646.
51. Manjeshwar S., Branam D.E., Lerner M.R., Brackett D.J., Jupe E.R. Tumor suppression by the prohibitin gene 3'untranslated region RNA in human breast cancer. Cancer Res. 2003, 63:5251-5256.
52. Manjeshwar S., Lerner M.R., Zang X.P., Branam D.E., Pento J.T., Lane M.M., Lightfoot S.A., Brackett D.J., Jupe E.R. Expression of prohibitin 3' untranslated region suppressor RNA alters morphology and inhibits motility of breast cancer cells. J. Mol. Histol. 2004, 35:639-646.
53. Jupe E.R., Badgett A.A., Neas B.R., Craft M.A., Mitchell D.S., Resta R., Mulvihill J.J., Aston C.E., Thompson L.F. Single nucleotide polymorphism in prohibitin 39 untranslated region and breast-cancer susceptibility. Lancet 2001, 357:1588-1589.
54. Fusaro G., Dasgupta P., Rastogi S., Joshi B., Chellappan S. Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J. Biol. Chem. 2003, 278:47853-47861.
55. Chander H., Halpern M., Resnick-Silverman L., Manfredi J.J., Germain D. Skp2B attenuates p53 function by inhibiting prohibitin. EMBO Rep. 2009, 11:220-225.
56. Wang S., Nath N., Adlam M., Chellappan S. Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene 1999, 18:3501-3510.
57. Wang S., Zhang B., Faller D.V. Prohibitin requires Brg-1 and Brm for the repression of E2F and cell growth. EMBO J. 2002, 21:3019-3028.
58. Dart D.A., Spencer-Dene B., Gamble S.C., Waxman J., Bevan C.L. Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours. Endocr. Relat. Cancer 2009, 16:1157-1169.
59. Liu T., Tang H., Lang Y., Liu M., Li X. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett. 2009, 273:233-242.
60. Ko K.S., Tomasi M.L., Iglesias-Ara A., French B.A., French S.W., Ramani K., Lozano J.J., Oh P., He L., Stiles B.L., Li T.W., Yang H., Martinez-Chantar M.L., Mato J.M., Lu S.C. Liver-specific deletion of prohibitin 1 results in spontaneous liver injury, fibrosis, and hepatocellular carcinoma in mice. Hepatology 2010.
61. Rajalingam K., Wunder C., Brinkmann V., Churin Y., Hekman M., Sievers C., Rapp U.R., Rudel T. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat. Cell Biol. 2005, 7:837-843.
62. Rajalingam K., Rudel T. Ras-Raf signaling needs prohibitin. Cell Cycle 2005, 4:1503-1505.
63. Patel N., Chatterjee S.K., Vrbanac V., Chung I., Mu C.J., Olsen R.R., Waghorne C., Zetter B.R. Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells. Proc. Natl Acad. Sci. USA 2010, 107:2503-2508.
64. van der Veen B.S., de Winther M.P., Heeringa P. Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxid. Redox Signal. 2009, 11:2899-2937.
65. Lih-Brody L., Powell S.R., Collier K.P., Reddy G.M., Cerchia R., Kahn E., Weissman G.S., Katz S., Floyd R.A., McKinley M.J., Fisher S.E., Mullin G.E. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig. Dis. Sci. 1996, 41:2078-2086.
66. Rachmilewitz D., Stamler J.S., Bachwich D., Karmeli F., Ackerman Z., Podolsky D.K. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Gut 1995, 36:718-723.
67. Shiratora Y., Aoki S., Takada H., Kiriyama H., Ohto K., Hai K., Teraoka H., Matano S., Matsumoto K., Kamii K. Oxygen-derived free radical generating capacity of polymorphonuclear cells in patients with ulcerative colitis. Digestion 1989, 44:163-171.
68. McKenzie S.J., Baker M.S., Buffinton G.D., Doe W.F. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J. Clin. Invest. 1996, 98:136-141.
69. Sido B., Hack V., Hochlehnert A., Lipps H., Herfarth C., Droge W. Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease. Gut 1998, 42:485-492.
70. Tamaki H., Nakamura H., Nishio A., Nakase H., Ueno S., Uza N., Kido M., Inoue S., Mikami S., Asada M., Kiriya K., Kitamura H., Ohashi S., Fukui T., Kawasaki K., Matsuura M., Ishii Y., Okazaki K., Yodoi J., Chiba T. Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology 2006, 131:1110-1121.
71. Segui J., Gironella M., Sans M., Granell S., Gil F., Gimeno M., Coronel P., Pique J.M., Panes J. Superoxide dismutase ameliorates TNBS-induced colitis by reducing oxidative stress, adhesion molecule expression, and leukocyte recruitment into the inflamed intestine. J. Leukoc. Biol. 2004, 76:537-544.
72. Ardite E., Sans M., Panes J., Romero F.J., Pique J.M., Fernandez-Checa J.C. Replenishment of glutathione levels improves mucosal function in experimental acute colitis. Lab. Invest. 2000, 80:735-744.
73. Kruidenier L., van Meeteren M.E., Kuiper I., Jaarsma D., Lamers C.B., Zijlstra F.J., Verspaget H.W. Attenuated mild colonic inflammation and improved survival from severe DSS-colitis of transgenic Cu/Zn-SOD mice. Free Radic. Biol. Med. 2003, 34:753-765.
74. Musch M.W., Walsh-Reitz M.M., Chang E.B. Roles of ZO-1, occludin, and actin in oxidant-induced barrier disruption. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G222-G231.
75. Sheth P., Basuroy S., Li C., Naren A.P., Rao R.K. Role of phosphatidylinositol 3-kinase in oxidative stress-induced disruption of tight junctions. J. Biol. Chem. 2003, 278:49239-49245.
76. von Ritter C., Grisham M.B., Hollwarth M., Inauen W., Granger D.N. Neutrophil-derived oxidants mediate formyl-methionyl-leucyl-phenylalanine-induced increases in mucosal permeability in rats. Gastroenterology 1989, 97:778-780.
77. Kruidenier L., Kuiper I., Lamers C.B., Verspaget H.W. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J. Pathol. 2003, 201:28-36.
78. Bartsch H., Nair J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch. Surg. 2006, 391:499-510.
79. Miles A.M., Grisham M.B. Antioxidant properties of aminosalicylates. Meth. Enzymol. 1994, 234:555-572.
80. Emerit J., Pelletier S., Likforman J., Pasquier C., Thuillier A. Phase II trial of copper zinc superoxide dismutase (CuZn SOD) in the treatment of Crohn's disease. Free Radic. Res. Commun. 1991, 12-13(Pt 2):563-569.
81. Niwa Y., Somiya K., Michelson A.M., Puget K. Effect of liposomal-encapsulated superoxide dismutase on active oxygen-related human disorders. A preliminary study. Free. Radic. Res. Commun. 1985, 1:137-153.
82. Hsieh S.Y., Shih T.C., Yeh C.Y., Lin C.J., Chou Y.Y., Lee Y.S. Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics 2006, 6:5322-5331.
83. Theiss A.L., Jenkins A.K., Okoro N.I., Klapproth J.M., Merlin D., Sitaraman S.V. Prohibitin inhibits tumor necrosis factor alpha-induced nuclear factor-kappa B nuclear translocation via the novel mechanism of decreasing importin alpha3 expression. Mol. Biol. Cell 2009, 20:4412-4423.
84. Kao W.H., Puddey I.B., Boland L.L., Watson R.L., Brancati F.L. Alcohol consumption and the risk of type 2 diabetes mellitus: atherosclerosis risk in communities study. Am. J. Epidemiol. 2001, 154:748-757.
85. de la Monte S.M., Neely T.R., Cannon J., Wands J.R. Ethanol impairs insulin-stimulated mitochondrial function in cerebellar granule neurons. Cell. Mol. Life Sci. 2001, 58:1950-1960.
86. Patel D.G., Singh S.P. Effect of ethanol and its metabolites on glucose mediated insulin release from isolated islets of rats. Metabolism 1979, 28:85-89.
87. Suh S.K., Hood B.L., Kim B.J., Conrads T.P., Veenstra T.D., Song B.J. Identification of oxidized mitochondrial proteins in alcohol-exposed human hepatoma cells and mouse liver. Proteomics 2004, 4:3401-3412.
88. Lee J.H., Nguyen K.H., Mishra S., Nyomba B.L. Prohibitin is expressed in pancreatic beta-cells and protects against oxidative and proapoptotic effects of ethanol. FEBS J. 2009, 277:488-500.
89. Vessal M., Mishra S., Moulik S., Murphy L.J. Prohibitin attenuates insulin-stimulated glucose and fatty acid oxidation in adipose tissue by inhibition of pyruvate carboxylase. FEBS J. 2006, 273:568-576.
90. Ande S.R., Moulik S., Mishra S. Interaction between O-GlcNAc modification and tyrosine phosphorylation of prohibitin: implication for a novel binary switch. PLoS ONE 2009, 4:e4586.
91. Copeland R.J., Bullen J.W., Hart G.W. Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E17-E28.
92. Kolonin M.G., Saha P.K., Chan L., Pasqualini R., Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat. Med. 2004, 10:625-632.
93. Hossen M.N., Kajimoto K., Akita H., Hyodo M., Ishitsuka T., Harashima H. Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue. J. Control. Release 2010, 147:261-268.